BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

460 related articles for article (PubMed ID: 15583480)

  • 1. Effects of HMG-CoA reductase inhibition on hepatic expression of key cholesterol-regulatory enzymes and receptors in nephrotic syndrome.
    Vaziri ND; Liang K
    Am J Nephrol; 2004; 24(6):606-13. PubMed ID: 15583480
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HMG-CoA reductase, cholesterol 7alpha-hydroxylase, LCAT, ACAT, LDL receptor, and SRB-1 in hereditary analbuminemia.
    Liang K; Vaziri ND
    Kidney Int; 2003 Jul; 64(1):192-8. PubMed ID: 12787409
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HMG-CoA reductase inhibition reverses LCAT and LDL receptor deficiencies and improves HDL in rats with chronic renal failure.
    Liang K; Kim CH; Vaziri ND
    Am J Physiol Renal Physiol; 2005 Mar; 288(3):F539-44. PubMed ID: 15507547
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Acyl-coenzyme A:cholesterol acyltransferase inhibition ameliorates proteinuria, hyperlipidemia, lecithin-cholesterol acyltransferase, SRB-1, and low-denisty lipoprotein receptor deficiencies in nephrotic syndrome.
    Vaziri ND; Liang KH
    Circulation; 2004 Jul; 110(4):419-25. PubMed ID: 15262831
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular mechanisms of altered cholesterol metabolism in rats with spontaneous focal glomerulosclerosis.
    Vaziri ND; Sato T; Liang K
    Kidney Int; 2003 May; 63(5):1756-63. PubMed ID: 12675851
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HMG-CoA reductase, cholesterol 7alpha-hydroxylase, LDL receptor, SR-B1, and ACAT in diet-induced syndrome X.
    Roberts CK; Liang K; Barnard RJ; Kim CH; Vaziri ND
    Kidney Int; 2004 Oct; 66(4):1503-11. PubMed ID: 15458444
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ACAT inhibition reverses LCAT deficiency and improves plasma HDL in chronic renal failure.
    Vaziri ND; Liang K
    Am J Physiol Renal Physiol; 2004 Nov; 287(5):F1038-43. PubMed ID: 15280162
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Upregulation of hepatic LDL receptor-related protein in nephrotic syndrome: response to statin therapy.
    Kim S; Kim CH; Vaziri ND
    Am J Physiol Endocrinol Metab; 2005 Apr; 288(4):E813-7. PubMed ID: 15585592
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Up-regulation of acyl-coenzyme A:cholesterol acyltransferase (ACAT) in nephrotic syndrome.
    Vaziri ND; Liang K
    Kidney Int; 2002 May; 61(5):1769-75. PubMed ID: 11967026
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of cyclosporine on HMG-CoA reductase, cholesterol 7alpha-hydroxylase, LDL receptor, HDL receptor, VLDL receptor, and lipoprotein lipase expressions.
    Vaziri ND; Liang K; Azad H
    J Pharmacol Exp Ther; 2000 Aug; 294(2):778-83. PubMed ID: 10900260
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hepatic tissue sterol regulatory element binding protein 2 and low-density lipoprotein receptor in nephrotic syndrome.
    Kim CH; Kim HJ; Mitsuhashi M; Vaziri ND
    Metabolism; 2007 Oct; 56(10):1377-82. PubMed ID: 17884448
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Studies of alteration of hepatic cholesterol metabolism in puromycin-induced nephrotic syndrome in rats.
    Thabet MA; Challa A; Chan JC; Pandak WM; Heuman DM; Vlahcevic ZR
    Kidney Int; 1993 Oct; 44(4):789-94. PubMed ID: 8258956
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of gender on hepatic HMG-CoA reductase, cholesterol 7alpha-hydroxylase, and LDL receptor in hereditary analbuminemia.
    Shin Y; Vaziri ND; Willekes N; Kim CH; Joles JA
    Am J Physiol Endocrinol Metab; 2005 Dec; 289(6):E993-8. PubMed ID: 16030068
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Influence of pravastatin, a specific inhibitor of HMG-CoA reductase, on hepatic metabolism of cholesterol.
    Reihnér E; Rudling M; Ståhlberg D; Berglund L; Ewerth S; Björkhem I; Einarsson K; Angelin B
    N Engl J Med; 1990 Jul; 323(4):224-8. PubMed ID: 2114543
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An egg-enriched diet attenuates plasma lipids and mediates cholesterol metabolism of high-cholesterol fed rats.
    Yang F; Ma M; Xu J; Yu X; Qiu N
    Lipids; 2012 Mar; 47(3):269-77. PubMed ID: 22234516
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Up-regulation of hepatic Acyl CoA: Diacylglycerol acyltransferase-1 (DGAT-1) expression in nephrotic syndrome.
    Vaziri ND; Kim CH; Phan D; Kim S; Liang K
    Kidney Int; 2004 Jul; 66(1):262-7. PubMed ID: 15200432
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Astragalus mongholicus and Angelica sinensis compound alleviates nephrotic hyperlipidemia in rats.
    Li J; Yu L; Li N; Wang H
    Chin Med J (Engl); 2000 Apr; 113(4):310-4. PubMed ID: 11775225
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Down-regulation of hepatic high-density lipoprotein receptor, SR-B1, in nephrotic syndrome.
    Liang K; Vaziri ND
    Kidney Int; 1999 Aug; 56(2):621-6. PubMed ID: 10432401
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Regulation of ovarian cholesterol metabolism: control of 3-hydroxy-3-methylglutaryl coenzyme A reductase and acyl coenzyme A:cholesterol acyltransferase.
    Schuler LA; Toaff ME; Strauss JF
    Endocrinology; 1981 Apr; 108(4):1476-86. PubMed ID: 7472277
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Acquired lecithin-cholesterol acyltransferase deficiency in nephrotic syndrome.
    Vaziri ND; Liang K; Parks JS
    Am J Physiol Renal Physiol; 2001 May; 280(5):F823-8. PubMed ID: 11292624
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.